Introduction
C hronic obstructive pulmonary disease (COPD) is currently ranked the fifth leading cause of global disability (health loss). 1 The Burden of Obstructive Lung Disease (BOLD) study estimates that the prevalence of COPD, defined according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria as stage 2 or higher, was 7.5% among Australian people aged 40 years or older in 2006-2010. 2 The prevalence of COPD was highest among people aged 75 years or older. 2 A recent report by Access Economics estimates that COPD cost the Australian economy about $98 billion in 2008. 3 Since Australia's population is ageing, the projected rise in the health burden of COPD will undoubtedly cause significant stress on the national healthcare system. Effective treatments to slow the progression of COPD and/or prevent exacerbations will likely result in significant health and economic benefits.
Chronic obstructive pulmonary disease is characterized by persistent airflow limitation that is usually progressive and associated with chronic inflammation in the airways and lungs from exposure to noxious particles or gases. 4 Prolonged exposure to noxious particles and gases is likely to bring about a chronic (innate and adaptive) inflammatory response in COPD patients which increases production and accumulation of mucus, infiltration of the airway walls by inflammatory cells, thickening of the airway wall and narrowing of the lumen. 5 The progression of COPD (i.e. an increase in the severity of airflow limitation by the GOLD grading system) is positively associated with the degree of the inflammatory response, 6 and the narrowing and disappearance of the small conducting airways. 7 In addition, prospective cohort studies have shown that airway and systemic inflammation, independent of smoking, increases the risk of worsening lung function and exacerbations, which, in turn, are associated with reduced survival. 8 Another cohort study observed decreases in airway and systemic inflammation in COPD patients hospitalized for acute exacerbation at the time of discharge (i.e. after treatment and recovery). 9 Although there is considerable uncertainty about the origin and role of inflammation in COPD, this body of evidence suggests that new therapies for reducing the chronic inflammatory response might improve COPD prognosis.
Low dietary intake of omega-3 fatty acids may be a novel reversible risk factor for chronic inflammation, and subsequent functional decline, in COPD patients, through a variety of mechanisms, including cell surface and intracellular receptors, that control inflammatory cell signalling and gene expression. 10 The major food sources of omega-3 fatty acids -docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) -are fish, fish oils and animal tissues (brain), whereas some plant oils contain a-linolenic acid (ALA).
11 Omega-6 fatty acids are predominately derived from plant oils, although small amounts of animal tissues contain g-linoleic acid (GLA) and arachidonic acid. 11 Omega-3 and omega-6 fatty acids have competitive (inhibiting) interactions that are important in modulating inflammation. 12 Epidemiological evidence (cross-sectional and prospective cohort studies) consistently shows an inverse association between dietary intake of omega-3 fatty acids and systemic inflammation across different populations including people with COPD. 13 -16 Moreover, the most recent systematic review and meta-analysis of relevant randomized controlled trials (RCTs) show that short-term marine-derived omega-3 supplementation significantly reduces systemic inflammatory biomarkers including Creactive protein (CRP), interleukin 6 (IL-6) and tumour necrosis factor a (TNF-a) in different population groups. 17 The effectiveness of omega-3 supplementation for lowering inflammatory markers was most evident in patients with cardiovascular risk factors, which are highly prevalent in COPD patients. 18 In contrast, two cross-sectional studies on omega-6 fatty acids reported opposing associations between dietary intake of arachidonic acid and systemic inflammation. 13, 16 Although the systematic review by Li et al. 17 is an excellent synthesis of evidence on effectiveness, none of the studies reviewed focussed on COPD patients. Furthermore, the equivocal results reported in one RCT raise questions about whether a reduction in chronic inflammation with polyunsaturated fatty acid (PUFA) supplementation is actually beneficial in patients with COPD. 19 For instance, a cross-sectional study found no evidence of benefit and several adverse associations between dietary intake of individual omega-3 and omega-6 fatty acids and airflow limitation in a regionally representative sample of Dutch adults. 20 To our knowledge, there is no completed or in-progress systematic review of evidence on this topic. We therefore sought to systematically assess relevant studies on the association of dietary intake and supplementation of specific PUFAs with inflammatory markers and functional capacity outcomes in COPD to inform guidelines and clinical practice.
Objectives
This review sought to identify the association of dietary intake and supplementation of specific PUFAs with chronic inflammation and functional capacity outcomes in people with COPD. More specifically, the objectives were the following:
(1) To identify the association of low dietary intake of omega-3 fatty acids (DHA, EPA or ALA) and/or omega-6 (GLA or arachidonic acid) fatty acids with chronic inflammation and functional capacity outcomes in people with COPD compared with controls (high dietary intake reference group).
(2) To identify the effectiveness of omega-3 fatty acid supplementation (containing predominantly one or more omega-3 fatty acids) in reducing chronic inflammation and improving functional capacity outcomes compared with placebo/no intervention in people with COPD.
Protocol
The Joanna Briggs Institute (JBI) protocol 21 has been registered with PROSPERO, the International Prospective Register of Systematic Reviews hosted by the Centre for Reviews and Dissemination (Registration Number is CRD42015015847).
Inclusion criteria

Types of participants
This review considered studies that included people with chronic lung disease within the spectrum of COPDrelated diagnoses (i.e. emphysema or chronic bronchitis).
Types of intervention(s)/phenomena of interest
This review considered observational studies that evaluate dietary intake of omega-3 (EPA, DHA or ALA) and/or omega-6 fatty acids (GLA or AA), and experimental studies that evaluate omega-3 fatty acid supplementation (containing predominantly one or more omega-3 fatty acids).
Types of studies
This review considered both experimental and nonexperimental (observational) study designs including RCTs, non-RCTs, quasi-experimental, before and after studies, prospective and retrospective cohort studies, case-control studies and cross-sectional studies for inclusion.
Types of outcomes
This review considered studies that included the following outcome measures: airway and systemic inflammatory markers and functional capacity outcomes. Inflammatory markers included, but were not limited to, CRP, TNF-a and interleukins. Functional capacity outcomes included, but were not limited to, exercise-based physical performance measures (e.g. muscle strength and endurance), and health status or health-related quality of life (HRQoL) measures.
Search strategy
The search strategy aimed to find both published and unpublished studies. A three-step search strategy was utilized in this review. An initial limited search of CINAHL was undertaken followed by an analysis of the text words contained in the title and abstract, and of the index terms used to describe the article. A second search was conducted independently by two reviewers using all identified keywords and index terms across all included databases. Thirdly, the reference list of all identified reports and articles was searched for additional studies. Studies published in English prior to August 2014 were considered for inclusion in this review. When possible, efforts were made to contact authors for information about unpublished trials. Details and examples of full electronic database search strategies appear in the appendix (Appendix I).
Assessment of methodological quality
Papers selected for retrieval were assessed by two independent reviewers for methodological quality using the standardized critical appraisal instruments from the JBI Meta Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI). 22 Any disagreements that arose between the reviewers were resolved through discussion.
Data collection
Data were extracted from papers included in the review independently by two reviewers using the standardized data extraction tools from JBI-MAStARI. 22 The data extracted included specific details about the interventions, populations, study methods and outcomes.
Data synthesis
Since statistical pooling was not possible because of the diverse types of studies reviewed, the findings were presented in narrative form, including tables to aid in data presentation, when appropriate.
Results
The search strategy identified 187 citations after duplicates were removed (Fig. 1) . Nine potentially eligible citations were identified after the first screening of titles and/or abstracts. After further screening, seven citations were excluded resulting in two eligible studies for review (Appendix II).
Description of studies
Study characteristics of two studies included for review appear in Table 1 . The RCT was conducted in 80 clinically stable COPD patients admitted to an inpatient pulmonary rehabilitation centre between 2000 and 2002 in the Netherlands (Asthma Center Hornerheide, Horn, the Netherlands). 19 The RCT was conducted in predominately male patients (about 70%), with a mean age of 63 years and without malignancies, gastrointestinal or kidney abnormalities, metabolic or endocrine diseases,
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International Journal of Evidence-Based Healthcare ß 2016 University of Adelaide, Joanna Briggs Institute and traditional 'inflammatory diseases'. The RCT investigated the effect of nine 1-g capsules daily, containing a total dose of 3.4 g PUFA (400 mg stearidonic acid; 760 mg GLA; 1200 mg ALA; 700 mg EPA; 340 mg DHA) on changes in exercise capacity, lung function and systemic inflammation outcomes at 8 weeks. All capsules were enriched with 3.5 mg/g vitamin E to 'stabilize the oil and to serve as an antioxidant'. The placebo-controlled comparison group was administered nine 1-g capsules daily, containing 80% palm oil and 20% sunflower oil, and the same caloric (9 kcal/capsule) and vitamin E content as the PUFA capsules administered in the experimental group. The PUFA supplementation significantly improved exercise capacity compared with the control condition [between-group difference in mean peak workload was 9.7 W (2.5-17.0; P ¼ 0.009); and mean duration was 4.3 min (0.6-7.9; P ¼ 0.023)]. Betweengroup differences in other outcomes were not statistically significant.
The cross-sectional study was conducted in 250 out of 342 COPD patients recruited during their first hospital admission at one of the nine university hospitals in Spain between January 2004 and March 2006. Patients had confirmed diagnosis of COPD, and were clinically stable for at least 3 months after discharge, and had dietary PUFA data and outcome data available. 13 They were predominately male patients (94%), with a mean age of 68 years. The study investigated the associations of exposure to high daily dietary intake of specific PUFAs and of omega-3 to omega-6 PUFA ratios with measures of systematic inflammation, using levels of inflammatory markers [TNF-a, IL-6, IL-8 and high-sensitivity C-reactive protein (hs-CRP)]; the median values discriminating between high and low level systemic inflammation. Daily dietary PUFA intake was estimated from analysis of dietary habits over the past 2 years. The comparison non-exposure condition was low PUFA intake (below the median). The study reported the following associations: high ALA was associated with decreased odds of high TNF-a [odds ratio (OR) 0.46, 95% confidence interval (CI) 0.21-0.99, P ¼ 0.49]; high DHA/arachidonic acid was associated with increased odds of high TNF-a (OR COPD, chronic obstructive pulmonary disease; LA, linoleic acid; PR, pulmonary rehabilitation; FEV1/FVC, forced expiratory volume in the first second to forced vital capacity ratio; hs-CRP, high-sensitivity C-reactive protein; PUFA, polyunsaturated fatty acid.
International Journal of Evidence-Based Healthcare ß 2016 University of Adelaide, Joanna Briggs Institute 3.02, 95% CI 1.03 to 8.91, P ¼ 0.045), which is in the opposite direction to what is expected; high arachidonic acid was associated with increased odds of high IL-6 (OR 1.96, 95% CI 1.05-3.64, P ¼ 0.034) and hs-CRP (OR 1.95, 95% CI 1.03-3.66, P ¼ 0.039). Other associations were not statistically significant.
Methodological quality
The RCT was well-conducted and had 8 of the 10 quality items (Appendix III), but lacked details about methods used for randomization and blinding. The cross-sectional study was well conducted and had five of the six applicable quality items (Appendix III), but did not use a random sampling procedure.
Discussion
On the basis of limited evidence of effectiveness from one 8-week RCT [National Health and Medical Research Council (NHMRC) Level II] 23 conducted in the Netherlands 19 and aetiological evidence from one cross-sectional study (NHMRC Level IV) conducted in Spain, 13 there is only weak support for the use of omega-3 fatty acid supplementation to reduce chronic inflammation and some support to improve functional capacity in COPD patients (NHMRC grade C). Specifically, there is no evidence showing that low dietary intake of specific omega-3 fatty acids worsens inflammation and/or function, nor evidence about the effectiveness of specific types and combinations of omega-3 fatty acids, appropriate dosing and duration of treatment required for improving inflammation and/or function. Thus, despite their excellent safety profile, wide availability, low cost and feasibility for implementation, recommendations for omega-3 fatty acid supplementation in patients with COPD should be applied with caution in country-specific healthcare settings.
The size of the effect (i.e. benefit) of mixed omega-3 fatty acids on exercise capacity observed in the RCT was large (increase from baseline was approximately 33%) and would likely be clinically relevant to COPD patients 24 and their clinicians. 25 However, the improvements in exercise capacity found in the RCT could not be attributed to a decrease in systemic inflammation, since no changes were observed in plasma IL-6, TNF-a or hs-CRP. This suggests that omega-3 fatty acids may improve exercise capacity through other physiological mechanisms including improvements in endothelial function and skeletal muscle metabolism. For example, a systematic review of RCTs conducted mostly in adults showed that supplementation of omega-3 fatty acids significantly improves endothelial function (assessed by flow-mediated dilation and endothelium-independent vasodilation) at a daily dose ranging from 0.45 to 4.5 g in the short term (over a median of 56 days). 26 Previous research shows that endothelial function is a strong predictor of exercise capacity. [27] [28] [29] In addition, supplementation of omega-3 fatty acids alters mitochondrial membrane composition and respiration kinetics in human skeletal muscle, which may improve exercise capacity through improvements in metabolic efficiency during exercise. 30 In contrast, the lack of effectiveness for reducing chronic inflammation is at odds with the positive findings in a previous systematic review, which showed that marine-derived omega-3 fatty acid supplementation significantly reduced CRP, IL-6 and TNF-a levels in other (non-COPD) population groups. 17 It is possible that the daily dose of omega-3 fatty acids in the RCT 19 reviewed was inadequate, since subgroup analysis in the systematic review revealed that significant reductions in hs-CRP and TNF-a were largest in the group of studies with dosing equal to or above the median daily dose of total omega-3 fatty acids and EPA. 17 Alternatively, the anti-inflammatory effect/benefit of omega-3 fatty acid supplementation may have been exaggerated and attributable to the type of placebo used in the previous studies, resulting in bias. For instance, subgroup analysis in the previous systematic review revealed that the size of the effect of omega-3 fatty acids on hs-CRP was larger and statistically significant [weighted mean difference was À0.22 (À0.33 to À0.11) vs. 0.03 (À0.13 to 0.20)] only when linoleic acid (LA) (an omega-6 fatty acid) was the major fatty acid used for placebo rather than oleic acid (an omega-9 fatty acid). 17 High (above median) daily dietary intake of LA was associated with increased crude odds of high hs-CRP (OR 1.67, 95% CI 1.02-2.76) in the cross-sectional study reviewed herein. 13 Conversely, the RCT evidence reviewed herein suggests that LA supplementation (8 g of safflower oil daily for 16 weeks) effectively reduces serum CRP levels. Given the conflicting effectiveness evidence on inflammation, the degree of bias, if any, attributable to the use of LA as placebo is unclear.
Several limitations require further consideration. Limitations in the RCT reviewed herein include analysis of study completers, use of a placebo containing potentially pro-inflammatory supplements (palm oil) 31, 32 and that results may not be relevant to other COPD populations (patients with common comorbidities, and in other countries). Limitations of the cross-sectional study include recall bias and uncertainty about the applicability of the results to other COPD populations (female patients, patients with recent or frequent exacerbations and other countries). Finally, reviewer-level limitations include incomplete retrieval of information for several of the citations excluded, and the existence of other relevant studies not identified by the search strategy, potentially resulting in bias. However, this level of bias was likely minimal since the results and conclusions reported in the three citations excluded because complete information could not be retrieved, were conflicting.
Conclusion
Collectively, the results of this review provide weak support for the routine use of omega-3 fatty acid supplementation for reducing chronic inflammation, and some support for improving functional capacity in COPD patients. Furthermore, there was no consistent evidence showing that low dietary intake of specific omega-3 fatty acids worsens inflammation and/or function. The generation of new research evidence should focus on the effectiveness of specific types and combinations of omega-3 fatty acids, the appropriate doses and duration of treatment required to improve inflammation and/or function and on the risks or benefits of low dietary intake of specific PUFAs, with a view to informing healthcare policy makers, COPD patients and their clinicians.
